Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA

Exclusion Criteria

• •1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;
• •2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;
• •3. PNH clone ≥ 50%;
• •4. Received HSCT before enrollment;
• •5. Received ATG treatment before enrollment;
• •6. Severe bleeding or infection that cannot be controlled by standard treatment;
• •7. Allergic or intolerant to romiplostim N01;
• •8. Active infections of HIV, HCV, or HBV, liver cirrhosis, or portal hypertension
• •9. History of malignant tumors within 5 years;
• •10. History of arterial or venous thrombosis;
• •11. Pregnant or lactating patients;
• •12. Participated in other clinical trials within 3 months.